Pharmacological Activity of LHT-17-19 in Cultures of Egfr-Expressing Epithelial Tumors

Abstract

Abstract. . In the study, the pharmacological activity of the pyridine derivative LHT-17-19 was studied in relation to the culture of pancreatic cancer cells PANC-1 and the culture of bladder cancer cells HT-29 expressing the epidermal growth factor receptor. The cultures were obtained from the library of tumor strains of the Moscow Research Institute of Oncology. P.A. Herzen - a separate structural subdivision of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia. LHT-17-19 was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of JSC VNTs BAV (Russia). LHT-17-19 and the reference drug "Doxorubicin" 50 mg each were added to the cultivation medium in the concentration range from 10-8 to 10-v. Compounds LHT-17-19 were shown to be able to induce death and suppress the growth of pancreatic cancer squamous culture (PANC-1) and bladder (HT-29) tumor cells expressing EGFR over a wide range of concentrations. So for pancreatic cancer (PANC-1), the effective inhibitory concentration for the compound LHT-17-19 was 1.3 × 10-7 M, while for the reference substance doxorubicin it was 6.0 × 10-5 M. bubble (NT-29) - 2.4 × 10-7 M and 5.2 × 10-4 M, respectively.